In Danish data, GLP-1 treatment reduces long-term sickness leave by 17.3%. Estimated total fiscal benefits of GLP-1 initiation are approximately 1.3–1.5% of annual labor income per employed individual. www.nber.org/papers/w35475

The Labor Market Impacts of GLP-1s

Founded in 1920, the NBER is a private, non-profit, non-partisan organization dedicated to conducting economic research and to disseminating research findings among academics, public policy makers, an...

nber.org

GLP-1 treatment cuts long-term sickness leave by 17 percent in Danish admin data, with fiscal benefits of 1.3–1.5 percent of annual earnings, but no impacts on income or employment, from Daysal, Fredrickson, Kristiansen, Trandafir, and @jzhangecon.bsky.social www.nber.org/papers/w35475

@nber.org digest today summarizing our GLP-1 work: www.nber.org/digest/20260...

The Health and Healthcare Spending Effects of GLP-1s

nber.org

Check out our new work on in utero exposure to opioids!

PNAS Nexus@pnasnexus.org · 5mo ago

Children and teens who were exposed to opioids in utero face enduring deficits in health, education, and social well-being, according to a study of administrative data linked to nearly 900,000 children in British Columbia, Canada. In PNAS Nexus: https://ow.ly/1QRm50YrSSE

Examining GLP-1s usage using data on 1.4M diabetic or obese veterans finds that PCP adoption drives large metabolic improvements matching trials—but no short-run cuts to emergency department use or medical spending, from Bock, Moshfegh, and @jzhangecon.bsky.social www.nber.org/papers/w34667

Two new preprints on the efx of GLP-1s just dropped. They use different samples, data, & designs. But they come to the same conclusion on one point: GLP-1s do not generate meaningful short- to medium-run reductions in non-GLP-1 medical spending, despite clear health benefits.

🚨Do GLP-1s “pay for themselves”? We study real-world impacts at scale. An estimated 1 in 8 Americans have tried GLP-1s. But beyond clinical trials, we know surprisingly little about their real-world effects. Paper: nber.org/papers/w34667 (w/ @jasminmoshfegh.bsky.social & Sam Bock) 🧵1/10

Weighing the Impacts of GLP-1s: Quasi-Experimental Evidence From Provider Adoption

Founded in 1920, the NBER is a private, non-profit, non-partisan organization dedicated to conducting economic research and to disseminating research findings among academics, public policy makers, an...

nber.org

We examine how bias in a widely used medical device against individuals with darker skin tones propagates into disparities in subsequent medical treatment

NBER@nber.org · 11mo ago

Black patients systematically receive lower rates of follow-up care than white patients even when the screening results would suggest they should receive higher rates of care, from @marcellaalsan.bsky.social‬, Liran Einav, Amy Finkelstein, and Jonathan Zhang https://www.nber.org/papers/w34168